Form 4: ENDRA CEO Granted 75,000 Restricted Stock Units

ENDRA Life Sciences CEO Alexander Y. Tokman was granted 75,000 restricted stock units, vesting in full on January 21, 2027.

Summary

• Alexander Y. Tokman, Chief Executive Officer and Director of ENDRA Life Sciences Inc. (NDRA), acquired 75,000 restricted stock units (RSUs).
• These RSUs convert to common stock on a one-for-one basis.
• The RSUs will vest in full on January 21, 2027.
• Following this transaction, Mr. Tokman's beneficial ownership totals 75,005 shares of common stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to the CEO is a standard compensation practice that aligns management's long-term interests with those of shareholders, indicating a stable governance structure regarding executive incentives. This is a neutral to slightly positive event, not directly impacting operational performance.

Positives

• The grant of restricted stock units to the CEO aligns management's long-term interests with those of shareholders, promoting a focus on sustained company performance.

Industry Context

Insider transactions, such as the grant of restricted stock units, are a common form of executive compensation across industries. These grants are typically designed to incentivize long-term performance and align the interests of executives with those of shareholders.

Related Party Transactions

• Grant of 75,000 restricted stock units to CEO Alexander Y. Tokman as part of his compensation package.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial incentives with the company's long-term stock performance, potentially benefiting shareholders through improved governance and strategic focus.

Next Steps

• The 75,000 restricted stock units are scheduled to vest in full on January 21, 2027.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to the CEO, which aligns management incentives with shareholder interests. However, it does not provide sufficient operational or financial data to warrant a change in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

ENDRA Life Sciences, NDRA, Alexander Y. Tokman, CEO, Director, Restricted Stock Units, RSU, Stock Grant, Insider Transaction, Form 4